Stefan Faderl

38.3k citations

570 papers · 27.0k indexed · 3 hit papers · h-index 88

Hematology top 0.01%
Genetics top 0.01%
Molecular Biology top 0.5%
Public Health, Environmental and Occupational Health top 0.05%
Oncology top 0.2%

Co-authors: Hagop M. Kantarjian Jörge E. Cortes Susan O’Brien Guillermo Garcia‐Manero Francis J. Giles Zeev Estrov Moshe Talpaz Deborah A. Thomas
Topics: Acute Myeloid Leukemia Research (272 papers)Chronic Lymphocytic Leukemia Research (263 papers)Chronic Myeloid Leukemia Treatments (190 papers)
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States United Kingdom Japan

In The Last Decade

Stefan Faderl

557 papers receiving 26.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Biology of Chronic Myeloid Leukemia

1999 975 citations Stefan Faderl, Moshe Talpaz et al. profile →
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

2003 631 citations Guillermo Garcia‐Manero, Francis J. Giles et al. Blood profile →

Peers

Countries citing papers authored by Stefan Faderl

Since Specialization

Citations

This map shows the geographic impact of Stefan Faderl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Faderl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Faderl more than expected).

Fields of papers citing papers by Stefan Faderl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Faderl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Faderl. The network helps show where Stefan Faderl may publish in the future.

Co-authorship network of co-authors of Stefan Faderl

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Faderl. A scholar is included among the top collaborators of Stefan Faderl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Faderl. Stefan Faderl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) 2017 ·Blood ·James McCloskey,(unknown),(unknown),Tracy Andrews,(unknown),(unknown),(unknown),Stuart L. Goldberg,Stefan Faderl	1
2	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia 2014 ·Clinical Cancer Research ·Marina Konopleva,Roland B. Walter,Stefan Faderl,Elias Jabbour,Zhihong Zeng,Gautam Borthakur,Xuelin Huang,Tapan M. Kadia,Peter P. Ruvolo,Jennie B. Feliu,Hongbo Lu,(unknown),Jan A. Burger,Michael Andreeff,Wenbin Liu,Keith Baggerly,Steven M. Kornblau,L. Austin Doyle,Elihu H. Estey,Hagop M. Kantarjian	70
3	Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) 2013 ·Blood ·Patricia Ault,(unknown),Hagop M. Kantarjian,Guillermo Garcia‐Manero,Alfonso Quintás‐Cardama,Gautam Borthakur,Stefan Faderl,Elias Jabbour,Charles S. Cleeland,Jörge E. Cortes	5
4	Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia 2012 ·Journal of Clinical Oncology ·Xavier C. Badoux,Michael J. Keating,Sijin Wen,William G. Wierda,Susan O’Brien,Stefan Faderl,Rachel L. Sargent,Jan A. Burger,Alessandra Ferrajoli	113
5	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemiabreakdown → 2012 ·Journal of Clinical Oncology ·Hagop M. Kantarjian,Xavier Thomas,Anna Dmoszyńska,Agnieszka Wierzbowska,Grzegorz Mazur,Jiří Mayer,Jyh-Pyng Gau,Wen‐Chien Chou,Rena Buckstein,Jaroslav Čermák,Ching-Yuan Kuo,Albert Oriol,Farhad Ravandi,Stefan Faderl,Jacques Delaunay,Daniel Lysák,Mark D. Minden,Christopher Arthur	818
6	A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome 2010 ·Cancer ·Elias Jabbour,Hagop M. Kantarjian,Farhad Ravandi,Guillermo Garcia‐Manero,Zeev Estrov,Srđan Verstovšek,Susan O’Brien,Stefan Faderl,Deborah A. Thomas,James R. Wright,Jörge E. Cortes	32
7	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients 2008 ·Blood ·Mikkael A. Sekeres,Paul Elson,Matt Kalaycio,Anjali S. Advani,Edward A. Copelan,Stefan Faderl,Hagop M. Kantarjian,Elihu H. Estey	146
8	Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia 2008 ·Journal of Clinical Oncology ·Alison Gardner,Gloria Mattiuzzi,Stefan Faderl,Gautam Borthakur,Guillermo Garcia‐Manero,Sherry Pierce,Mark Brandt,Elihu H. Estey	84
9	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome 2008 ·Blood ·Stefan Faderl,Farhad Ravandi,Xuelin Huang,Guillermo Garcia‐Manero,Alessandra Ferrajoli,Zeev Estrov,Gautam Borthakur,Srđan Verstovšek,Deborah A. Thomas,Monica Kwari,Hagop M. Kantarjian	151
10	Hematologic malignancies : acute leukemias 2008 ·Springer eBooks ·Elihu H. Estey,Stefan Faderl,Hagop M. Kantarjian	17
11	The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia 2008 ·Cancer ·Ahmed Aribi,Hagop M. Kantarjian,Charles Koller,Deborah A. Thomas,Stefan Faderl,Guillermo Garcia‐Manero,Jörge E. Cortes	10
12	Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure 2007 ·Cancer ·Jörge E. Cortes,Alfonso Quintás‐Cardama,Guillermo Garcia‐Manero,Susan O’Brien,Dan Jones,Stefan Faderl,(unknown),Francis J. Giles,Deborah A. Thomas,Hagop M. Kantarjian	31
13	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia 2005 ·Blood ·Elihu H. Estey,Guillermo Garcia‐Manero,Alessandra Ferrajoli,Stefan Faderl,Srđan Verstovšek,Dan Jones,Hagop M. Kantarjian	261
14	Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy 2005 ·Cancer ·Gautam Borthakur,Hagop M. Kantarjian,George Q. Daley,Moshe Talpaz,Susan O’Brien,Guillermo Garcia‐Manero,Francis J. Giles,Stefan Faderl,Mary M. Sugrue,Jörge E. Cortes	52
15	Significance of myelofibrosis in early chronic‐phase, chronic myelogenous leukemia on imatinib mesylate therapy 2005 ·Cancer ·Hagop M. Kantarjian,(unknown),Moshe Talpaz,Susan O’Brien,Francis J. Giles,Stefan Faderl,William G. Wierda,Mary Beth Rios,Jianqin Shan,Jörge E. Cortes	11
16	Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy 2004 ·Cancer ·Gloria Mattiuzzi,Hagop M. Kantarjian,Stefan Faderl,JoAnn Lim,Dimitrios P. Kontoyiannis,Deborah A. Thomas,William G. Wierda,I. Raad,Guillermo Garcia‐Manero,Xian Zhou,(unknown),N. Bekele,Elihu H. Estey	30
17	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon‐α regimens for early chronic phase 2003 ·Cancer ·Hagop M. Kantarjian,Susan O’Brien,Jörge E. Cortes,Jianqin Shan,Francis J. Giles,Guillermo Garcia‐Manero,Srđan Verstovšek,Stefan Faderl,Mary Beth Rios,Moshe Talpaz	13
18	Hematopoietic Recovery Following Induction Therapy of Acute Leukemias: Prognostic Implications and a New Look at the Definition of Remission 2003 ·Leukemia & lymphoma ·Stefan Faderl,Zeev Estrov	13
19	The Clinical Significance of Caspase Regulation in Acute Leukemia 2001 ·Leukemia & lymphoma ·Stefan Faderl,Zeev Estrov	6
20	Hematopoietec growth factors and cytokines 2000 ·Stefan Faderl,Zeev Estrov	1

About Stefan Faderl

Stefan Faderl is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 570 papers that have together received 27.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (272 papers), Chronic Lymphocytic Leukemia Research (263 papers) and Chronic Myeloid Leukemia Treatments (190 papers). The work is most often cited by research in Hematology (17.0k citations), Genetics (10.9k citations) and Pathology and Forensic Medicine (4.8k citations). Stefan Faderl has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Guillermo Garcia‐Manero, Francis J. Giles, Zeev Estrov, Moshe Talpaz, Deborah A. Thomas, Farhad Ravandi and Alessandra Ferrajoli. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact